Becton Dickinson announced that it received 510(k) clearance from the US Food and Drug Administration for a high-throughput assay to detect vaginitis.

Owlstone Medical and Bicycle Therapeutics said that the firms will collaborate on research into breath-based early cancer detection tests that would combine Bicycle's proprietary bicyclic peptides with Owlstone's exogenous volatile organic compound probes.

Cue Health Inc., a healthcare technology company, reported financial results for the fourth quarter and full-year 2022.

On March 14, 2023, Agilent Technologies announced the establishment of an innovation collaboration lab with Alta Scientific Co., Ltd.

Oxford Gene Technology announced that eight of its CytoCell fluorescence in situ hybridization probes have been certified for clinical use in line with Europe's In Vitro Diagnostics Regulation (IVDR).

Visby Medical said that it has received 510(k) clearance and a CLIA waiver from the US Food and Drug Administration for its second-generation point-of-care sexual health test.

On 13 March, BioMérieux China signed a strategic cooperation agreement with Accunome Biotechnology Co., Ltd.

Cue Health, a healthcare technology company, announced the nationwide launch of a new suite of consumer-friendly, at-home diagnostic test kits.

Leica Biosystems and Paige announced that they are expanding their previously announced digital pathology partnership. ​

On March 10, 2023, Shenzhen MGI Tech Co.,Ltd. and Yeasen Biotechnology (Shanghai) Co., Ltd. officially reached a strategic cooperation to promote the localization of high-throughput sequencing (NGS) reagents and instruments in China.

Agilent Technologies announced a multiyear distribution agreement with Proscia to offer a comprehensive digital diagnostic pathology system.

Virax Biolabs Group has reached an agreement for the supply of an Avian Influenza A Virus (AIV) real-time PCR test kit in the European Union (EU) region, or CE mark-accepting markets.

In October 2022, the Office of the Leading Group for Deepening Medical and Health System Reform in Shanghai issued the Notice on Piloting the High-Quality Development of Public Hospitals in Shanghai.

QIAGEN announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).

Japanese healthcare firm Sysmex said that it has signed a global supply agreement for hemostasis instruments and reagents with Siemens Healthineers.​